DR. MARTIN STEINHOFF, M.D.
Dermatology at Divisadero St, San Francisco, CA

License number
California F5514
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
1701 Divisadero St, San Francisco, CA 94115
Phone
(415) 353-7888
(415) 476-0936 (Fax)

Personal information

See more information about MARTIN STEINHOFF at radaris.com
Name
Address
Phone
Martin Steinhoff
1460 5Th Ave, San Francisco, CA 94122
(415) 682-4645
Martin Steinhoff
San Francisco, CA
(415) 682-4645

Organization information

See more information about MARTIN STEINHOFF at bizstanding.com

Martin Steinhoff MD,PHD

1701 Divisadero St, San Francisco, CA 94115

Industry:
Dermatologist
Phone:
(415) 353-7800 (Phone)
Martin Steinhoff

Professional information

Martin Steinhoff Photo 1

Dr. Martin Steinhoff, San Francisco CA - MD (Doctor of Medicine)

Specialties:
Dermatology
Address:
Ucsf/Mount Zion Medical Center
1701 Divisadero St SUITE 4TH, San Francisco 94115
(415) 353-7688 (Phone)
UNIVERSITY OF CALIFORNIA SAN FRANCISCO DERMATOLOGY
1701 Divisadero St SUITE 3RD, San Francisco 94115
(415) 353-7800 (Phone), (415) 353-7870 (Fax)
Languages:
English
Education:
Medical School
Philipps-Universitaet Marburg, Fachbereich Medizin
Graduated: 1995


Martin Steinhoff Photo 2

Professor At Ucsf Medical Center

Position:
Professor at UCSF Medical Center
Location:
San Francisco Bay Area
Industry:
Hospital & Health Care
Work:
UCSF Medical Center - Professor


Martin Steinhoff Photo 3

Professor Of Dermatology And Surgery At Ucsf Medical Center

Position:
Professor of Dermatology and Surgery at UCSF Medical Center
Location:
San Francisco Bay Area
Industry:
Hospital & Health Care
Work:
UCSF Medical Center - Professor of Dermatology and Surgery


Martin Steinhoff Photo 4

Markers And Method For The Diagnosis Of Rosacea

US Patent:
2013001, Jan 17, 2013
Filed:
Dec 16, 2010
Appl. No.:
13/516834
Inventors:
Jérôme Aubert - Grasse, FR
Martin Steinhoff - San Francisco CA, US
Michel Rivier - Nice, FR
Johannes Voegel - Chateauneuf/Grasse, FR
Assignee:
UNIVERSITAT MUNSTER - Munster
GALDERMA RESEARCH & DEVELOPMENT - Biot
International Classification:
C40B 30/04, A61B 10/02
US Classification:
506 9, 600562
Abstract:
Markers for rosacea among the chemokines and cytokines and their receptors, selected from interleukin 8 (IL-8), CXCL1, CXCL2, CXCL3 and CXCL5, the CXCR1 receptor and the CXCR2 receptor are described. Also described, is a method for the diagnosis of rosacea.


Martin Steinhoff Photo 5

Modulators For Trpa1 For The Treatment Of Rosacea

US Patent:
2014002, Jan 23, 2014
Filed:
Dec 19, 2011
Appl. No.:
13/997134
Inventors:
Jéróme Aubert - Grasse, FR
Martin Steinhoff - San Francisco CA, US
International Classification:
A61K 45/00, G01N 33/50
US Classification:
514789, 435 792, 260 1
Abstract:
An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRP) cation channel, subfamily A, member 1(TRPA1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.


Martin Steinhoff Photo 6

Modulators And Methods For The Treatment Of Rosacea

US Patent:
2014003, Jan 30, 2014
Filed:
Dec 19, 2011
Appl. No.:
13/997110
Inventors:
Jerome Aubert - Grasse, FR
Martin Steinhoff - San Francisco CA, US
Assignee:
UNIVERSITAT MUNSTER - Munster
GALDERMA RESEARCH & DEVELOPMENT - Biot
International Classification:
A61K 31/55, A61K 31/357, A61K 31/496, A61K 31/506, A61K 31/538, A61K 31/4439, A61K 31/416, A61K 31/4725, A61K 31/4188, A61K 31/165, A61K 31/451
US Classification:
51421301, 540593, 564161, 514617, 549362, 514452, 544360, 51425301, 544319, 514269, 546206, 514319, 544327, 514256, 5462791, 514343, 5483621, 514406, 546 15, 514278, 544284, 51426621, 5483011, 514389, 544105, 5142305, 435 721
Abstract:
An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.


Martin Steinhoff Photo 7

Pacap Signaling Pathway Modulators For Treating Inflammatory Skin Diseases Having A Neurogenic Component, Notably Rosacea, And Compositions Comprised Thereof

US Patent:
2011022, Sep 22, 2011
Filed:
Jul 17, 2009
Appl. No.:
13/054769
Inventors:
Johannes Voegel - Grasse, FR
Michel Rivier - Nice, FR
Jerome Aubert - Grasse, FR
Martin Steinhoff - San Francisco CA, US
Assignee:
Galderma Research & Development - Biot
International Classification:
A61K 31/713, G01N 33/566, C12Q 1/68, C07H 21/02, A61P 29/00, A61P 17/10, A61P 17/02, A61P 17/00, A61P 31/00, A61P 31/04, A61P 31/12, A61P 33/00, A61P 31/10, A61P 23/00, A61P 37/08, A61P 39/06, A61P 37/06, A61P 17/08, A61P 17/12, A61Q 17/04, A61P 3/02
US Classification:
424 59, 435 792, 435 613, 536 245, 436501, 514 44 A, 435 617
Abstract:
Modulators of specific PACAP receptors are useful for treating inflammatory skin diseases having a neurogenic component, and more particularly rosacea and/or facial erythema, compositions containing these and screening methods are described for identifying PACAP signaling pathway modulators.